Compare Neurocrine Biosciences Inc (NBIX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Veritone Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Veritone Inc trades at $0.87 (market cap $85.83M). The key difference: Neurocrine Biosciences Inc is far larger — about 183.7× Veritone Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | VERI | |
|---|---|---|
Market Cap | $15.77B | $85.83M |
Sector | Health | Technology |
52-Week High | $185.50 | $8.39 |
52-Week Low | $123.10 | $0.79 |
Enterprise Value | $15.78B | $121.22M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Veritone (VERI) trades at $0.9155, up 0.99% on the day, amid a bearish technical signal with mixed oscillators. The company reported Q2 2026 revenue of $24.3 million, up 20% sequentially, but continues to post significant losses, with a net income margin of -117.54% in 2025. Recent news highlights a securities class action investigation announced by Kaskela Law on August 20, 2026, adding legal overhangs to operational challenges.
The outlook remains challenged by persistent unprofitability and negative cash flow from operations, offset by a balanced analyst consensus of 46% buy and 46% hold ratings. Key risks include ongoing legal scrutiny, high operating costs, and the need to achieve sustainable profitability to support the stock's valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
